Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study

Kingswood, J. Chris, Bissler, John J., Budde, Klemens, Hulbert, John, Guay-Woodford, Lisa, Sampson, Julian Roy, Sauter, Matthias, Cox, Jane, Patel, Uday, Elmslie, Frances, Anderson, Chris and Zonnenberg, Bernard A. 2016. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study. Nephron Clinical Practice 134 (2) , pp. 51-58. 10.1159/000448293

[thumbnail of JCK_Kingswood revision d1 201603029.pdf]
PDF - Accepted Post-Print Version
Download (541kB) | Preview


Renal-related disease is the most common cause of tuberous sclerosis complex (TSC)-related death in adults, and renal angiomyolipomas can lead to complications that include chronic kidney disease (CKD) and hemorrhage. International TSC guidelines recommend mammalian target of rapamycin (mTOR) inhibitors as first-line therapy for management of asymptomatic, growing angiomyolipomas >3 cm in diameter. This review discusses data regarding patient outcomes that were used to develop current guidelines for embolization of renal angiomyolipomas and presents recent data on 2 available mTOR inhibitors - sirolimus and everolimus - in the treatment of angiomyolipoma. TSC-associated renal angiomyolipomas can recur after embolization. Both sirolimus and everolimus have shown effectiveness in reduction of angiomyolipoma volume, with an acceptable safety profile that includes preservation of renal function with long-term therapy. The authors propose a hypothesis for mTORC1 haploinsufficiency as an additional mechanism for CKD and propose that preventive therapy with mTOR inhibitors might have a role in reducing the number of angiomyolipoma-related deaths. Because mTOR inhibitors target the underlying pathophysiology of TSC, patients might benefit from treatment of multiple manifestations with one systemic therapy. Based on recent evidence, new guidelines should be considered that support the earlier initiation of mTOR inhibitor therapy for the management of renal angiomyolipomas to prevent future serious complications, rather than try to rescue patients after the complications have occurred.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Karger
ISSN: 1660-8151
Date of First Compliant Deposit: 2 February 2018
Date of Acceptance: 6 July 2016
Last Modified: 27 Jun 2019 23:19

Citation Data

Cited 38 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics